ライフサイエンスコーパス: endoscopic therapy

1 ients with T1b disease may also benefit from endoscopic therapy.

2 Forrest grade Ia to IIb ulcers were offered endoscopic therapy.

3 and intravenous proton pump inhibitor after endoscopic therapy.

4 indispensable component following successful endoscopic therapy.

5 in the vast majority of patients undergoing endoscopic therapy.

6 CLE, and the technique may be used to guide endoscopic therapy.

7 omy are recurrent and refractory to standard endoscopic therapy.

8 to a shift in treatment algorithms favoring endoscopic therapy.

9 r stigmata of recent hemorrhage and need for endoscopic therapy.

10 e resolution after no more than 12 months of endoscopic therapy.

11 ation-induced telangiectasias is amenable to endoscopic therapy.

12 g medical conditions which require immediate endoscopic therapy.

13 decrease complication rates associated with endoscopic therapy.

14 S) have lower rebleeding rates compared with endoscopic therapy.

15 are limited because most have already failed endoscopic therapy.

16 an emphasis on novel imaging techniques and endoscopic therapies.

17 % vs. 10%, P < 0.01), and to be managed with endoscopic therapy (79% vs. 17%, P < 0.01).

18 Endoscopic therapy achieves hemostasis in >90% of bleedi

19 There was no difference between endoscopic therapy and medical therapy in length of hosp

20 ife-threatening bleeding was unresponsive to endoscopic therapy and other surgical procedures.

21 Rebleeding occurs in 20% of patients after endoscopic therapy, and so can we provide better outcome

22 malignant disease remains controversial, and endoscopic therapies appear promising.

23 the efficacy and safety of pharmacologic or endoscopic therapies as primary prophylaxis or that prev

24 Endoscopic therapy as primary or secondary prophylaxis o

25 ng patients with achalasia continue to offer endoscopic therapies before recommending operative myoto

26 g Heller myotomy for achalasia, 154 received endoscopic therapy before being referred for surgery (10

27 cation, magnetic sphincter augmentation, and endoscopic therapies can benefit patients with well-char

28 to medical treatment with beta-blockers and endoscopic therapy can be managed by variceal decompress

29 Endoscopic therapy (Deflux) has demonstrated moderate su

30 There has been an increase in interest in endoscopic therapy (ET) for intramucosal (T1a) or submuc

31 g stigmata of recent hemorrhage and need for endoscopic therapy, even when tested in an external pati

32 orporeal shockwave lithotripsy combined with endoscopic therapy failed to benefit patients with calci

33 ry was necessary in 12 patients (3.7%) after endoscopic therapy failed.

34 red in patients in whom the first attempt at endoscopic therapy fails.

35 Research and clinical experience with the endoscopic therapies for Barrett's esophagus continue to

36 garding the durability and role of different endoscopic therapies for dysplastic Barrett's oesophagus

37 Endoscopic therapies for gastroesophageal reflux disease

38 nt for development of medical, surgical, and endoscopic therapies for GERD.

39 Endoscopic therapy for achalasia should not be used unle

40 POEM is an endoscopic therapy for achalasia with a shorter hospital

41 m toxin injection is the most common initial endoscopic therapy for achalasia, most likely due to its

42 rcinoma (IMC) in light of recent advances in endoscopic therapy for Barrett's esophagus.

43 ween treatment groups and that the choice of endoscopic therapy for EVH must still rely on clinical g

44 ial recommendations of the AGA Institute on "Endoscopic Therapy for Gastroesophageal Reflux Disease."

45 anding of the indications and limitations of endoscopic therapy for HGD and IMC permits a tailored ap

46 py for HGD is preferred to surveillance, (6) endoscopic therapy for HGD is preferred to surgery, (7)

47 opy is necessary for accurate diagnosis, (5) endoscopic therapy for HGD is preferred to surveillance,

48 dose intravenous proton pump inhibitor after endoscopic therapy for peptic ulcer bleeding has been re

49 f the notable advances over the past year in endoscopic therapy for the esophagus.

50 No rebleeding followed endoscopic therapy for the ulcers.

51 Endoscopic therapy for UGIB in a resource-poor setting s

52 Patients who rebleed after endoscopic therapy for ulcer hemorrhage should be treate

53 The overall rebleeding rate for endoscopic therapy for varices was 16.7%.

54 Patients in the endoscopic therapy group underwent endoscopic clot remov

55 Patients in the endoscopic therapy group were less likely to undergo sur

56 g occurred in 5 of 61 (8.2%) patients in the endoscopic therapy group, compared with 21 of 85 (24.7%)

57 up period, none of the patients who received endoscopic therapy had a pseudocyst recurrence, compared

58 Adding proton pump inhibitors (PPIs) to endoscopic therapy has become the mainstay of treatment

59 Endoscopic therapy has been employed for early-stage les

60 inese patients remains poorly understood and endoscopic therapy has not been well established.

61 Endoscopic therapies have a role in temporizing active v

62 Endoscopic therapies have become an indispensable modali

63 ents in the treatment of these sequelae, new endoscopic therapies have emerged to treat gastroesophag

64 Endoscopic therapy improves the outcome of nonvariceal u

65 ntion (median, 178 days) revealed successful endoscopic therapy in 43 (81%) and persistence of WOPN i

66 Advanced endoscopic therapies including mucosectomy or photodynam

67 Promising advances have been made in endoscopic therapy, including formalin, neodymium/yttriu

68 Endoscopic therapy is an appropriate option and recent e

69 Endoscopic therapy is appropriate for treating chronic p

70 Endoscopic therapy is effective in removing more than 80

71 Endoscopic therapy is emerging as an alternative to surg

72 Endoscopic therapy is highly effective and safe for pati

73 esectable disease and a favorable prognosis; endoscopic therapy is inappropriate.

74 Endoscopic therapy is now being proposed as a viable tre

75 Endoscopic therapy is superior to medical therapy for pr

76 diagnosed, treated, or palliated with timely endoscopic therapy, it is appropriate to consider endosc

77 Four Eras separated by the dates when endoscopic therapy (January 1981), liver transplantation

78 The sequential introduction of endoscopic therapy, liver transplantation, and TIPS has

79 tered during the past 2 decades during which endoscopic therapy, liver transplantation, and TIPS have

80 ve of this study was to assess the impact of endoscopic therapy, liver transplantation, and transjugu

81 Endoscopic therapy may be a viable management option for

82 However, there is some evidence that endoscopic therapy may be successful in benign disease a

83 Endoscopic therapy might be useful in some patients, but

84 were also published, as well as surgical and endoscopic therapy of pancreatitis.

85 hy in the evaluation of biliary disease, and endoscopic therapy of postoperative liver transplantatio

86 In contrast, the impact of endoscopic therapy on natural history remains unresolved

87 and should be factored into the decision for endoscopic therapy or esophagectomy

88 herent clot is controversial and may include endoscopic therapy or medical therapy.

89 patients with GERD to treatment with either endoscopic therapy or surgery according to the size of h

90 using EPCS mainly as salvage for failure of endoscopic therapy or TIPS is not supported by the defin

91 lcer hemorrhage should be treated by further endoscopic therapy, rather than urgent surgery.

92 Use of preoperative endoscopic therapy remains common and has resulted in mo

93 Endoscopic therapy should be performed on actively bleed

94 Endoscopic therapy should become the standard of care fo

95 Compared with endoscopic therapy, TIPS leads to lower recurrent varice

96 We analyzed data from a multicenter study of endoscopic therapy to identify factors associated with p

97 Endoscopic therapy was ain 90.5% of the cases.

98 Endoscopic therapy was applied using the heater probe fo

99 In 2002 several endoscopic therapies were reintroduced or modified.

100 risk bleeding peptic ulcers after successful endoscopic therapy were randomly assigned as oral lansop

101 overed at an early stage can be treated with endoscopic therapy, whereas advanced cancers are primari

102 the future, the less invasive alternative of endoscopic therapy will need to be balanced against the

103 achieving hemostasis for patients who failed endoscopic therapy with epinephrine injection, clip, or